Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mylan’s Fulphila: First Neulasta Biosimilar’s Road To US Market Slowed Only By Product Quality, GMP Deficiencies

Executive Summary

Mylan demonstrated analytical similarity, including for the PEG moiety, and the absence of clinically meaningful differences between MYL-1401H and Amgen’s pegfilgrastim during first review cycle, but it had to resubmit the application after FDA flagged concerns about the biosimilar’s manufacturing process and ongoing facility deficiencies.

Advertisement

Related Content

Keeping Track: FDA Starts November With A Bang
Mylan's Fulphila Sets Up The US Market For The Next Biosimilar Showdown
Mylan's Fulphila Approval: Lack Of US FDA AdComm May Be A Positive For Biosimilar Industry
US FDA's Biosimilars Program: Five Years In, Complete Response Letters Still Outnumber Approvals
How Biocon Site Prevented FDA 'OAI' Finding From Derailing Biosimilars
Neulasta Is 4-0 Versus Biosimilars Now That Mylan Has A CRL From FDA
Will FDA GMP Observations Stall Biocon’s Run?
Taking Biosimilars Down A PEG: Why Copying Neulasta Isn’t So Easy
Neulasta Biosimilar From Coherus Needs Better Immunogenicity Assay After Stumble At US FDA

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS124207

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel